Inpatient-Only Phase-Out: Rethinking Revenue Protection Strategies

As the Medicare Inpatient-Only (IPO) List phases out, hospitals and health systems face new revenue risk for procedures that no longer carry a default inpatient designation. For more than two decades, the list set a clear reimbursement boundary: the Centers for Medicare & Medicaid Services (CMS) paid for these procedures only in the inpatient setting, a standard most commercial and managed payers mirrored. Clinical teams, utilization review (UR) staff, physician advisors, and revenue cycle leaders relied on that boundary to guide site-of-care and billing decisions.

The phase-out takes this away.

Beginning in calendar year 2026, CMS finalized a three-year phase-out of the IPO List, removing 285 procedures in the first year, most of them musculoskeletal. CMS frames this change as one that gives beneficiaries more choice, reducing out-of-pocket costs where appropriate, and giving physicians more flexibility over site of service.

As usual, for hospitals and health systems, the implications of this major regulatory update extend well beyond patient and provider choice. With inpatient status no longer determined by the procedure itself, the burden of defending appropriate reimbursement shifts to each organization's clinical decision-making, provider documentation discipline, and revenue cycle coordination.

Why does the IPO phase-out create revenue risk?

The IPO phase-out creates revenue risk because reimbursement now depends on patient-specific clinical justification. A procedure that once followed a predictable inpatient pathway is now payable in an outpatient setting, meaning the burden of proof for inpatient status (and by extension the inpatient reimbursement) falls to the provider and supporting team members. Absolutely, physicians may still admit patients when the clinical circumstances support inpatient care, but the organization must be able to demonstrate, up front and in detail, why outpatient level of care was insufficient for each individual patient requiring inpatient admission for their procedure.

That demonstration depends on five things working together: authorization management, medical necessity documentation, utilization review, physician advisor support, and payer-specific criteria alignment. Gaps in any of these can lead to lower reimbursement, payer friction and challenges, and avoidable denials.

It should go without saying that the goal should not be to preserve inpatient volume regardless of clinical need. Rather, the goal should be to ensure that every site-of-care decision is clinically appropriate, operationally supported, and financially defensible.

Site-of-care decisions are now revenue decisions

Site-of-care decisions now, more than ever, connect clinical judgment to enterprise financial performance. What starts as a scheduling, authorization, or status determination issue carries through to reimbursement, payer scrutiny, denial volume, appeal workload, and, just as important as the rest, patient financial responsibility.

For healthcare leaders, this makes IPO readiness a cross-functional requirement for provider, facility, and/or enterprise success. Decisions that once sat largely within clinical operations or utilization review now require increased alignment across patient access, surgeon offices, prior authorization teams, utilization management, physician advisors, Clinical Documentation Integrity (CDI), medical coding, denials, compliance, and finance.

When each function works from a different view of the case, the organization creates avoidable exposure: authorization does not match clinical reality; documentation describes the procedure itself but fails to explain the patient-specific need for inpatient care; utilization review reaches out only after the best opportunity to appropriately improve documentation has passed; denials reveal recurring issues that never make their way back to scheduling or physician education with a dedicated feedback loop.

Revenue risk often begins before the claim

Denial prevention should start well in advance of claim submission. IPO-related denial exposure often begins at the point of procedure scheduling and payer authorization request.

Consider a seasoned authorization support team member in an orthopedic office: he is very used to scheduling inpatient admissions and requesting inpatient authorizations for posterior lumbar interbody fusions (PLIFs). Status-post the IPO updates for 2026, now a payer may spit out outpatient approval instead. The authorization team member may either accept the outpatient authorization without noticing it is not for inpatient level of care; alternatively, the surgeon, when alerted to the outpatient authorization, may not understand the implications for herself, the hospital, and the patient, and thus not take the opportunity to push for inpatient authorization. Utilization review reviews the case post-procedure, potentially flagging the appropriateness for inpatient level of care. Now, the hospital authorization team is chasing a retroactive inpatient authorization, or maybe the case slips through completely, with a 2-3 day stay billed and reimbursed as outpatient.

Regardless of how the scenario may play out, by the time a denial or underpayment presents itself, the most effective prevention points have already passed.

Identifying appropriate admission status and identifying reimbursement risk at the point of scheduling depends on pre-service visibility into this year’s removed procedures, payer authorization patterns, individual patient clinical complexity, and scheduling and authorization workflows and handoffs.

What visibility does leadership need?

Traditional denial reports provide a retrospective view of performance. Instead, leadership teams need indicators that reveal early on where financial exposure is developing.

Key measures include:

• Procedures affected by IPO changes, recorded for services provided and facility locations.
• Site-of-care shifts by payer, physician group, and procedure.
• Authorization approval patterns and status mismatches.
• Outpatient, observation, and inpatient conversion rates.
• Medical necessity denial and underpayment trends.
• Documentation deficiencies by procedure or physician group.
• Appeal outcomes, overturn rates, and time to resolution.
• Reimbursement variance across affected procedures.

These metrics expose operational vulnerabilities while there is still time to act on them, before they impact financial performance.

Financial exposure should be modeled, not assumed

The financial impact of IPO changes will vary widely by the hospital or health system. Procedure mix, payer mix, contracts, patient complexity, documentation quality, authorization accuracy, outpatient capacity, and physician practice patterns all matter.

A Trilliant Health analysis of the 285 procedures removed from the IPO List for 2026 found an average difference of about $16,334 between inpatient prospective payment system (IPPS) and outpatient prospective payment system (OPPS) reimbursement. That figure should be treated as a directional indicator, not a guaranteed loss per case. Still, it highlights why executives should model exposure rather than wait for denial volume or revenue variance to reveal the impact.

A useful model should identify where reimbursement risk is greatest, which procedures drive the most volume, how payer behavior varies, and where moving to outpatient could impact contribution margin. Rather than assume every case should remain inpatient, leaders need to understand where appropriate inpatient care must be supported by a stronger clinical and administrative record.

How should hospitals and health systems respond?

A strong executive response should combine governance, process discipline, analytics, and clinical revenue cycle expertise. Four top priorities should be:

• Create site-of-care governance. Define how affected procedures will be reviewed, who owns escalation decisions, and how conflicts between authorization, physician expectation, and clinical reality will be resolved.
• Strengthen pre-service review. Build workflows that identify high-risk procedures, complex patients, authorization mismatches, and medical necessity concerns before the patient arrives.
• Engage physician advisors earlier. Use physician advisors prospectively and concurrently, including before denials occur.
• Close the feedback loop. Turn denial and underpayment trends into upstream education for scheduling, authorization, utilization review, CDI, and physician teams.

This is where a revenue cycle management (RCM) partner with clinical administrative expertise can help hospitals and health systems scale oversight without adding strain to already stretched internal teams. A flexible delivery model supported by experienced clinical and revenue cycle professionals can extend capacity across authorization review, utilization management, physician advisory support, denials, and analytics.

FAQ